论文部分内容阅读
日本版NIH及其制药企业,政策制定·战略规划需要佐证。为此,本研究尝试基于新的指标体系进行制药产业的现状俯瞰与未来预测。连载第一篇,着眼于制药产业研究开发的pipeline,即在研药物。按照研究开发阶段来梳理pipeline,通过与已上市药物数量的比较,显然可以把握各国目前及未来的研发能力。该结果凸现出了美国在研发中的优势,以及日本的特异性等。
Japanese version of NIH and its pharmaceutical companies, policy formulation and strategic planning needs evidence. To this end, this study attempts to review the status quo and future of the pharmaceutical industry based on the new index system. Serial first, focusing on the pharmaceutical industry research and development pipeline, that is studying drugs. In accordance with the research and development stage to sort out the pipeline, with the number of listed drugs compared to Obviously can grasp the current and future research and development capabilities. This result highlights the U.S. advantage in research and development as well as Japan’s specificity.